36th annual San Antonio Breast Cancer Symposium. Resumen de lo más destacado

Among the many papers were presented at the 36th San Antonio Breast Cancer Symposium in 2013; the most important −mainly oral presentations−are summarized below. Notable for their clinical applicability were two studies on the management of the primary tumor in metastatic breast cancer and the PRIME II trial evaluating the impact of omitting adjuvant radiotherapy in elderly patients. The expected data from the BETH trial, evaluating the benefit of adding bevacizumab in the adjuvant treatment of HER2-positive tumors, were also reported, and interesting information was presented on the efficacy of carboplatin in triple-negative breast cancer. From the point of view of tumor biology, the organizers wanted to provide a platform for the potential role of immunity in the prognosis of breast cancer, and mutations in the estrogen receptor gene, which are emerging as a new mechanism of acquisition of hormone resistance.